Home > Newsletters > Drug Industry Daily > Jazz Gets Intermediate Victory in Patent Fight, Likely to Maintain Xyrem Exclusivity: Analyst
Drug Industry Daily
Aug. 2, 2012 | Vol. 11 No. 151
Jazz Gets Intermediate Victory in Patent Fight, Likely to Maintain Xyrem Exclusivity: Analyst
Jazz Pharmaceuticals received some positive, if minor, news in its legal battle to maintain exclusivity for its narcolepsy drug Xyrem this week when a district court denied generic-drug maker Roxane Laboratories’ request to submit additional evidence showing that Jazz’s patents are invalid.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.